Genetic Characterization of Patients With Arrhythmia-Induced Cardiomyopathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospital Universitario 12 de Octubre
About this trial
The goal of this observational study is to learn about the genetic insights of arrhythmya-induced cardiomyopathy and its clinical prognosis. The main questions it aims to answer are:
I. Does patients with arrhythmia-induced cardiomyopathy have a greater proportion of genetic mutations compared with other types of cardiomyopathy or general population? II. Have the genetics any prognostic impact in patients with arrhythmia-induced cardiomyopathy?
Eligibility criteria
Qualifiers
Presence of atrial fibrillation or atrial flutter not self-limited.
Performance of a cardiac imaging test with systolic function analysis (echocardiogram, magnetic resonance, CT scan) during the clinical course of the arrhythmia, exhibiting a left ventricular ejection fraction (LVEF) <50%. In order for the test to be representative, the maximum time between the performance of the imaging test and the rhythm control procedure will be 3 months, in the absence of intervening cardiovascular events that may have caused a variation in LVEF. In the event that the patient had a previously known LVEF <50%, the change with respect to this attributable to tachyarrhythmia has to be ≥10%.
Signature of informed consent.
Ability to understand and accept participation in the study.
Disqualifiers
Refusal of informed consent.
Legal or juridical incapacity.
Age <18 years.
Life expectancy less than 1 year.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
109 Participants
are grouped into 2 trial groupsSponsors and collaborators
Source ClinicalTrials.gov